In an offensive display of hubris and disregard for the public and the pandemic, @GileadSciences has priced at thousands of dollars a drug that should be in the public domain. Gilead’s price is 10x the cost-effective price ($310) suggested by ICER (no mortality benefit) (1/4) 
For $1 per day, remdesivir can be manufactured at scale with a reasonable profit. According to ICER, at $310 per course, remdesivir would be cost effective. Gilead has rejected both prices and has yet to show why the price should be higher. (2/4) icer-review.org/announcements/…
Gilead initially developed remdesivir as one of several candidate treatments for hep C and has made tens of billions off its successful hep C drugs. What's relevant now are Gilead’s unpublished costs & the public’s many investments repurposing remdesivir for COVID-19. (3/4)
Gilead did not make #remdesivir alone. Public funding was indispensable and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by Trump. (4/4) citizen.org/article/the-re…
